Ratio Therapeutics

Ratio Therapeutics is a pharmaceutical company focused on developing innovative radiopharmaceuticals for the treatment of cancer. The company's proprietary technology platforms, Trillium and Macropa, enable the imaging, discovery, and advancement of novel radiopharmaceuticals with tunable properties for enhanced tumor targeting, safety, and efficacy.

Trillium is a trifunctional small molecule scaffold that can be fine-tuned to alter its plasma clearance, target affinity, and therapeutic payload. This allows for independent optimization of tumor uptake and normal tissue clearance, maximizing the therapeutic index. Ratio has successfully applied this framework to several tumor targets and therapeutic payloads.

Macropa is a best-in-class chelator platform that facilitates the incorporation of the potent alpha-emitter Actinium-225 into radiotherapeutics. Macropa's unique chemistry enables ease of manufacture and robust stability, further enhancing the safety and efficacy of Ratio's radiopharmaceuticals.

Ratio's lead candidate is a fibroblast activation protein-alpha (FAP)-targeted radiotherapy for soft tissue sarcoma, which is scheduled to enter clinical trials by the end of 2024. In March 2024, the company expanded its manufacturing agreement with PharmaLogic to accelerate the development and commercialization of its FAP-targeted pipeline.

Ratio has established strategic collaborations with companies like Bayer, Lantheus, and Merck to develop targeted radiotherapeutics and diagnostics across various cancer indications. The company reported USD 90 million in total funding raised since its inception in 2021, including a USD 50 million Series B financing round in January 2024.